静脉-动脉体外膜氧合用于COVID-19患者循环衰竭:来自ECMOSARS登记研究的见解
ECMOSARS为法国多中心前瞻性全国登记研究,共纳入41个中心652例COVID-19需V-V/V-A ECMO患者,其中47例因难治性心源性休克接受VA-或VAV-ECMO。全队列院内生存率28%,排除E-CPR患者后为43%。作者认为E-CPR在此人群中不是VA-ECMO的合理适应证。
要点
- 47例COVID-19相关难治性心源性休克患者接受VA-或VAV-ECMO,中位年龄49岁。
- 全队列院内生存率28%,排除E-CPR患者后为43%。
- 作者建议E-CPR不是该人群VA-ECMO的合理适应证。
核心结论
- 作者报告了迄今针对COVID-19中VA-和VAV-ECMO接受者最大的聚焦分析。
- 尽管相对罕见,这些患者对临时机械循环支持的需求与不良预后相关。
- 然而,VA-ECMO仍是挽救经过仔细筛选患者的可行方案。
- 作者识别了与不良预后相关的因素,并建议E-CPR不是该人群VA-ECMO的合理适应证。
研究设计与样本
- ECMOSARS为法国多中心前瞻性全国登记研究,纳入COVID-19感染背景下需要V-V ECMO/VA-ECMO的患者,共41个中心652例。
- 本分析聚焦其中47例因难治性心源性休克接受VA-或VAV-ECMO支持的患者。
主要发现
- 患者中位年龄49岁,14%既往诊断为心力衰竭。
- 心源性休克最常见病因为急性肺栓塞(30%)、心肌炎(28%)和急性冠脉综合征(4%)。
- 38%的患者接受了体外心肺复苏(E-CPR)。
- 全队列院内生存率为28%,排除E-CPR患者后为43%。
- ECMO置管后第1天pH和FiO2显著改善,但非存活者此时酸中毒更严重且FiO2更高(P=0.030和P=0.006)。
关键数值与推荐
- 与死亡相关的其他因素包括:年龄更大(P=0.02)、体重指数更高(P=0.03)、E-CPR(P=0.001)、非心肌炎病因(P=0.02)、血清乳酸更高(P=0.004)、ECMO启动前使用肾上腺素(而非去甲肾上腺素)(P=0.003)、出血并发症(P=0.001)、输血需求更大(P=0.001)以及更严重的SAVE和SAFE评分(P=0.01和P=0.03)。
临床怎么用
- 作者认为VA-ECMO仍是挽救经过仔细筛选患者的可行方案。
- 作者建议E-CPR不是该人群VA-ECMO的合理适应证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The clinical profile and outcomes of patients with Coronavirus Disease 2019 (COVID-19) who require veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or veno-arterial-venous extracorporeal membrane oxygenation (VAV-ECMO) are poorly understood. We aimed to describe the characteristics and outcomes of these patients and to identify predictors of both favourable and unfavourable outcomes. METHODS: ECMOSARS is a multicentre, prospective, nationwide French registry enrolling patients who require veno-venous extracorporeal membrane oxygenation (ECMO)/VA-ECMO in the context of COVID-19 infection (652 patients at 41 centres). We focused on 47 patients supported with VA- or VAV-ECMO for refractory cardiogenic shock. RESULTS: The median age was 49. Fourteen percent of patients had a prior diagnosis of heart failure. The most common aetiologies of cardiogenic shock were acute pulmonary embolism (30%), myocarditis (28%) and acute coronary syndrome (4%). Extracorporeal cardiopulmonary resuscitation (E-CPR) occurred in 38%. In-hospital survival was 28% in the whole cohort, and 43% when E-CPR patients were excluded. ECMO cannulation was associated with significant improvements in pH and FiO2 on day 1, but non-survivors showed significantly more severe acidosis and higher FiO2 than survivors at this point (P = 0.030 and P = 0.006). Other factors associated with death were greater age (P = 0.02), higher body mass index (P = 0.03), E-CPR (P = 0.001), non-myocarditis aetiology (P = 0.02), higher serum lactates (P = 0.004), epinephrine (but not noradrenaline) use before initiation of ECMO (P = 0.003), haemorrhagic complications (P = 0.001), greater transfusion requirements (P = 0.001) and more severe Survival after Veno-Arterial ECMO (SAVE) and Sonographic Assessment of Intravascular Fluid Estimate (SAFE) scores (P = 0.01 and P = 0.03). CONCLUSIONS: We report the largest focused analysis of VA- and VAV-ECMO recipients in COVID-19. Although relatively rare, the need for temporary mechanical circulatory support in these patients is associated with poor prognosis. However, VA-ECMO remains a viable solution to rescue carefully selected patients. We identified factors associated with poor prognosis and suggest that E-CPR is not a reasonable indication for VA-ECMO in this population.
引用
- Anselmi A, Mansour A, Para M, et al. Veno-arterial extracorporeal membrane oxygenation for circulatory failure in COVID-19 patients: insights from the ECMOSARS registry. Eur J Cardiothorac Surg. 2023. PMID: 37280062. doi:10.1093/ejcts/ezad229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。